Interobserver Agreement Rates on Fibroblast Activation Protein Inhibitor-Directed Molecular Imaging and Therapy

被引:8
|
作者
Serfling, Sebastian E. [1 ]
Hartrampf, Philipp E. [1 ]
Zhi, Yingjun [2 ]
Higuchi, Takahiro [1 ,3 ]
Rowe, Steven P. [4 ]
Bundschuh, Lena [5 ]
Essler, Markus [5 ]
Buck, Andreas K. [1 ]
Bundschuh, Ralph Alexander [5 ]
Werner, Rudolf A. [1 ,4 ]
机构
[1] Julius Maximilian Univ Wurzburg, Dept Nucl Med, Univ Hosp Wurzburg, Wurzburg, Germany
[2] Julius Maximilian Univ Wurzburg, Dept Otorhinolaryngol Aesthet & Reconstruct Head, Wurzburg, Germany
[3] Okayama Univ, Fac Med Dent & Pharmaceut Sci, Okayama, Japan
[4] Johns Hopkins Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD USA
[5] Univ Hosp Bonn, Dept Nucl Med, Venusberg Campus 1, D-53127 Bonn, Germany
基金
日本学术振兴会;
关键词
fibroblast activation protein inhibitor; FAPI; molecular imaging; theranostics; endoradiotherapy; RADS; CANCER; CLASSIFICATION;
D O I
10.1097/RLU.0000000000004189
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objectives Fibroblast activation protein (FAP) has emerged as a novel target for FAP inhibitor (FAPI)-directed molecular imaging and endoradiotherapy (ERT). We aimed to assess the interobserver agreement rates for interpretation of Ga-68-FAPI-4 PET/CT and decision for ERT. Patients and Methods A random order of Ga-68-FAPI-4 PET/CTs from 49 oncology patients were independently interpreted by 4 blinded readers. Per scan, visual assessment was performed, including overall scan impression, number of organ/lymph node (LN) metastases, and number of affected organs/LN regions. Moreover, a maximum of 3 target lesions, defined as largest in size and/or most intense, per organ compartment were identified, which allowed for an additional quantitative interobserver assessment of LN and organ lesions. To investigate potential reference tissues, quantification also included unaffected liver parenchyma and blood pool. Readers also had to indicate whether FAPI-directed ERT should be considered (based on intensity of uptake and widespread disease). Interobserver agreement rates were evaluated using intraclass correlation coefficients (ICCs) and interpreted according to Cicchetti (with 0.4-0.59 indicating fair, and 0.6-0.74 good, agreement). Results On a visual basis, the agreement rate for an overall scan impression was fair (ICC, 0.42; 95% confidence interval [CI], 0.27-0.57). The concordance rate for number of affected LN areas was also fair (ICC, 0.59; 95% CI, 0.45-0.72), whereas the number of LN metastases, number of affected organs, and number of organ metastases achieved good agreement rates (ICC, >= 0.63). In a quantitative analysis, concordance rates for LN were good (ICC, 0.70; 0.48-0.88), but only fair for organ lesions (ICC, 0.43; 0.26-0.60). In regards to background tissues, ICCs were good for unaffected liver parenchyma (0.68; 0.54-0.79) and fair for blood pool (0.43; 0.29-0.58). When readers should decide on ERT, concordance rates were also fair (ICC, 0.59; 95% CI, 0.46-0.73). Conclusions For FAPI-directed molecular imaging and therapy, a fair to good interobserver agreement rate was achieved, supporting the adoption of this radiotracer for clinical routine and multicenter trials.
引用
收藏
页码:512 / 516
页数:5
相关论文
共 50 条
  • [31] Fibroblast Activation Protein Inhibitor Tracers and Their Preclinical, Translational, and Clinical Status in China
    Zhao, Liang
    Kang, Fei
    Pang, Yizhen
    Fang, Jianyang
    Sun, Long
    Wu, Hua
    Lan, XiaoLi
    Wang, Jing
    Chen, Haojun
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 : 4S - 11S
  • [32] Molecular imaging biomarkers for immune checkpoint inhibitor therapy
    van de Donk, Pim P.
    de Ruijter, Laura Kist
    Lub-de Hooge, Marjolijn N.
    Brouwers, Adrienne H.
    van der Wekken, Anthonie J.
    Oosting, Sjoukje F.
    Fehrmann, Rudolf S. N.
    de Groot, Derk Jan A.
    de Vries, Elisabeth G. E.
    THERANOSTICS, 2020, 10 (04): : 1708 - 1718
  • [33] Evaluation of a Novel Gd-FAPI Dimer Molecular Probe Targeting Fibroblast Activation Protein for Imaging of Solid Tumors
    Wang, Xiaohui
    Zhuang, Caiyu
    Zheng, Xinhui
    Zhang, Xiaolei
    Han, Zhijian
    Wu, Renhua
    MOLECULAR PHARMACEUTICS, 2025, 22 (03) : 1498 - 1506
  • [34] Fibroblast activation protein inhibitor-positron emission tomography in aortitis: fibroblast pathology in active inflammation and remission
    Roehrich, Manuel
    Rosales, Juan J.
    Hoppner, Jorge
    Kvacskay, Peter
    Blank, Norbert
    Loi, Lisa
    Paech, Daniel
    Schreckenberger, Mathias
    Giesel, Frederik
    Kauczor, Hans Ulrich
    Lorenz, Hanns Martin
    Haberkorn, Uwe
    Merkt, Wolfgang
    RHEUMATOLOGY, 2024, 63 (09) : 2473 - 2483
  • [35] New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress
    Imlimthan, Surachet
    Moon, Euy Sung
    Rathke, Hendrik
    Afshar-Oromieh, Ali
    Roesch, Frank
    Rominger, Axel
    Gourni, Eleni
    PHARMACEUTICALS, 2021, 14 (10)
  • [36] Fibroblast Activation Protein-Directed - Directed Imaging Outperforms 18 F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial
    Kessler, Lukas
    Schwaning, Felix
    Metzenmacher, Martin
    Pabst, Kim
    Siveke, Jens
    Trajkovic-Arsic, Marija
    Schaarschmidt, Benedikt
    Wiesweg, Marcel
    Aigner, Clemens
    Ploenes, Till
    Darwiche, Kaid
    Boeluekbas, Servet
    Stuschke, Martin
    Umutlu, Lale
    Nader, Michael
    Theegarten, Dirk
    Hamacher, Rainer
    Eberhardt, Wilfried E. E.
    Schuler, Martin
    Herrmann, Ken
    Fendler, Wolfgang P.
    Hautzel, Hubertus
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (08) : 1188 - 1193
  • [37] The Potential of Fibroblast Activation Protein-Targeted Imaging as a Biomarker of Cardiac Remodeling and Injury
    Maday Fernandez Mayola
    James T. Thackeray
    Current Cardiology Reports, 2023, 25 : 515 - 523
  • [38] Recent topics in fibroblast activation protein inhibitor-PET/CT: clinical and pharmacological aspects
    Yuji Nakamoto
    Shingo Baba
    Hayato Kaida
    Osamu Manabe
    Tomoya Uehara
    Annals of Nuclear Medicine, 2024, 38 : 10 - 19
  • [39] Fibroblast Activation Protein Inhibitor Theranostics: A Huge Opportunity with its Fair Share of Oncological Pitfalls
    Al-Ibraheem, Akram
    WORLD JOURNAL OF NUCLEAR MEDICINE, 2024, 23 (02) : 71 - 72
  • [40] Recent topics in fibroblast activation protein inhibitor-PET/CT: clinical and pharmacological aspects
    Nakamoto, Yuji
    Baba, Shingo
    Kaida, Hayato
    Manabe, Osamu
    Uehara, Tomoya
    ANNALS OF NUCLEAR MEDICINE, 2024, 38 (01) : 10 - 19